Clinical trials: Hyperkalaemia
Hyperkalemia
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil
This is a descriptive, retrospective study involving patients from private cardiology, nephrology, and dialysis clinics in Brazil who participated in the National Hyperkalaemia Diagnosis Campaign.
- Trial name
- HOPE (NCT07370194)
- Where
- Brazil
- Volunteers
- 6,215 people
- Sponsor
- AstraZeneca
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue…
- Trial name
- REALIZE-K (NCT04676646)
- Testing
- Sodium zirconium cyclosilicate, Spironolactone
- Where
- 89 sites in United States, Brazil and 6 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Hyperkalaemia Requiring Postoperative Dialysis, Metabolic Acidosis
Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants
In this study we want to show that the choice of a balanced type fluid solution for the perioperative fluid management of patients receiving cadaveric renal transplantation results in less occurrence of intra- and postoperative…
- Trial name
- NCT01075750
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Vienna
Peritoneal Dialysis
Effects of Renin-Angiotensin System Inhibitors in Peritoneal Dialysis Patients
Among antihypertensive medications, RAS inhibitor classes, namely angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) have the most prospective data on mortality and cardiovascular outcomes in…
- Trial name
- NCT04076930
- Testing
- angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)
- Where
- Thailand
- Volunteers
- 1,468 people
- Sponsor
- Chiang Mai University
Hyperkalemia
POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
This study assesses serum potassium and cardiac rhythm trends in subjects with end stage renal disease (ESRD) who are on 3 times weekly maintenance hemodialysis for at least 60 days.
- Trial name
- PORTEND (NCT02609841)
- Testing
- Cardiac rhythm remote monitoring system
- Where
- 9 sites in United States
- Volunteers
- 240 people
- Sponsor
- ZS Pharma, Inc.
Hyperkalemia
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels
- Trial name
- Redukx (NCT04780841)
- Testing
- RDX013
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Ardelyx
Hyperkalemia, Chronic Kidney Disease
Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG
This study aims to evaluate whether hyperkalemia, a potentially life-threatening condition in dialysis patients, can be detected early using a wearable single-lead ECG device.
- Trial name
- NCT07054905
- Testing
- HiCardi wearable ECG
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Kyungho Park
Hyperkalemia
A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG)
The purpose of this study is to validate the real-world performance of a previously developed Artificial Intelligence - Electrocardiogram (AI-ECG) algorithm for identification of hyperkalemia with a six-lead mobile-enhanced…
- Trial name
- REACT (NCT05441852)
- Where
- United States
- Volunteers
- 1,151 people
- Sponsor
- Mayo Clinic
Chronic Kidney Disease, Type 2 Diabetes
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.
- Trial name
- RAPID-CKD (NCT07547878)
- Testing
- Finerenone, Semaglutide, Lotensin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Baylor Research Institute
Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4
Patiromer and Diet/hrQoL in Chronic Dialysis
This is a phase III, prospective, randomized, double-blind, placebo-controlled, single-center, pilot trial, aimed at assessing whether treatment with the oral potassium binder patiromer as compared to placebo allows withdrawal or…
- Conditions
- Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4, Dietary Intervention
- Trial name
- PRINCE (NCT06858280)
- Testing
- Patiromer 8400 MG [Veltassa]
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Hyperkalemia, Hemolysis
Dietary Fiber and Hyperkalemia in Dialysis Patients
To analyze the dietary nutrition and dietary fiber (DF) intake of maintenance hemodialysis (MHD) patients, and explore the effect of dietary nutrition and DF intake balance on the nutritional status and pre-dialysis hyperkalemia…
- Trial name
- NCT05860491
- Testing
- dietary fiber
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qianfoshan Hospital
Chronic Kidney Diseases, Hyperkalemia
Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)
This study hypothesizes that the administration of Sodium zirconium cyclosilicate in CKD patients with hyperkalemia while avoiding dietary potassium restriction will normalize their serum potassium levels.
- Trial name
- NCT04727840
- Testing
- Sodium Zirconium Cyclosilicate Oral Product
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Hyperkalemia
Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among…
- Trial name
- NCT02088073
- Testing
- Sodium zirconium cyclosilicate
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 258 people
- Sponsor
- ZS Pharma, Inc.
Hyperkalemia
Patiromer With or Without Food for the Treatment of Hyperkalemia
The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high…
- Trial name
- TOURMALINE (NCT02694744)
- Testing
- patiromer
- Where
- 29 sites in United States
- Volunteers
- 114 people
- Sponsor
- Relypsa, Inc.
Hyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD)
Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network (HEKATE)
This is a cross-sectional retrospective study of laboratory records of patients who take electrolytes blood tests containing the data of the serum potassium level.
- Trial name
- NCT03657875
- Where
- Russia
- Volunteers
- 53,940 people
- Sponsor
- AstraZeneca
Hypertension
Increasing Potassium Intake in Hypertensive Individuals
This study evaluates the safety of increasing dietary potassium intake in a hypertensive population that may be at risk for hyperkalemia.
- Trial name
- NCT02759367
- Testing
- High potassium diet
- Volunteers
- 20 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Hyperkalemia, Renal Insufficiency, Chronic
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
This is a multicentre, 2-part, single-blind, randomised, withdrawal, placebo-controlled study, that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part…
- Trial name
- Patiromer JADE (NCT05136664)
- Testing
- Patiromer Powder for Oral Suspension (Part A), Patiromer Powder for Orals Suspension (Part B)
- Where
- 28 sites in China
- Volunteers
- 262 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Hyperkalemia, Heart Failure
Evaluation of Patiromer in Heart Failure Patients
The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
- Trial name
- PEARL-HF (NCT00868439)
- Testing
- patiromer
- Where
- 33 sites in United States, Czechia and 5 more
- Volunteers
- 120 people
- Sponsor
- Relypsa, Inc.
Dysequilibrium Syndrome, ESRD
Adding Urea to the Final Dialysis Fluid
At times patients with advanced renal failure present with severe hyperkalemia or acidosis and very high serum blood urea nitrogen (BUN) concentrations.
- Conditions
- Dysequilibrium Syndrome, ESRD, Hyperkalemia, Metabolic Acidosis
- Trial name
- Urea dialysate (NCT06366230)
- Testing
- Urea in the dialysate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Hyperkalemia
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase…
- Trial name
- NCT07251309
- Testing
- WS016
- Where
- 50 sites in China
- Volunteers
- 420 people
- Sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.